{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:53:27Z","timestamp":1786982007204,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["126601-MRSG-14-215-01-TBG"],"award-info":[{"award-number":["126601-MRSG-14-215-01-TBG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11523-019-00662-4","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T01:02:38Z","timestamp":1566176558000},"page":"563-575","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5674-6408","authenticated-orcid":false,"given":"Steven I.","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina P.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Angus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk P.","family":"Dittmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Foote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Parton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aadra P.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri D.","family":"Fedoriw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa L.","family":"Cann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blossom","family":"Damania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"key":"662_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5\u201329.","journal-title":"CA Cancer J Clin"},{"key":"662_CR2","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;328:1002\u20136.","journal-title":"N Engl J Med"},{"key":"662_CR3","first-page":"483","volume":"25","author":"JM Vose","year":"1998","unstructured":"Vose JM. Current approaches to the management of non-Hodgkin\u2019s lymphoma. Semin Oncol. 1998;25:483\u201391.","journal-title":"Semin Oncol"},{"key":"662_CR4","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","volume":"28","author":"S Barrans","year":"2010","unstructured":"Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28:3360\u20135.","journal-title":"J Clin Oncol"},{"key":"662_CR5","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","volume":"114","author":"KJ Savage","year":"2009","unstructured":"Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114:3533\u20137.","journal-title":"Blood"},{"key":"662_CR6","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1038\/leu.2008.230","volume":"22","author":"W Klapper","year":"2008","unstructured":"Klapper W, Stoecklein H, Zeynalova S, et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group (DSHNHL). Leukemia. 2008;22:2226\u20139.","journal-title":"Leukemia"},{"key":"662_CR7","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1038\/sj.onc.1202746","volume":"18","author":"CE Nesbit","year":"1999","unstructured":"Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene. 1999;18:3004\u201316.","journal-title":"Oncogene"},{"key":"662_CR8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1309\/YHFE-R65B-D3LK-3GGV","volume":"113","author":"CC Chang","year":"2000","unstructured":"Chang CC, Liu YC, Cleveland RP, et al. Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas. Am J Clin Pathol. 2000;113:512\u20138.","journal-title":"Am J Clin Pathol"},{"key":"662_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/ajh.1084","volume":"67","author":"KB Pagnano","year":"2001","unstructured":"Pagnano KB, Vassallo J, Lorand-Metze I, et al. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin\u2019s lymphomas. Am J Hematol. 2001;67:84\u201392.","journal-title":"Am J Hematol"},{"key":"662_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/01.LAB.0000057000.41585.FD","volume":"83","author":"AI Saez","year":"2003","unstructured":"Saez AI, Artiga MJ, Romero C, et al. Development of a real-time reverse transcription polymerase chain reaction assay for c-myc expression that allows the identification of a subset of c-myc\u2009+\u2009diffuse large B-cell lymphoma. Lab Invest. 2003;83:143\u201352.","journal-title":"Lab Invest"},{"key":"662_CR11","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1182\/blood-2008-02-137372","volume":"112","author":"LM Rimsza","year":"2008","unstructured":"Rimsza LM, Leblanc ML, Unger JM, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2008;112:3425\u201333.","journal-title":"Blood"},{"key":"662_CR12","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1182\/blood-2012-01-406033","volume":"119","author":"W Cuccuini","year":"2012","unstructured":"Cuccuini W, Briere J, Mounier N, et al. MYC\u2009+\u2009diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood. 2012;119:4619\u201324.","journal-title":"Blood"},{"key":"662_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/leu.2008.312","volume":"23","author":"HA Poirel","year":"2009","unstructured":"Poirel HA, Cairo MS, Heerema NA, et al. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin\u2019s lymphoma: results of the FAB\/LMB 96 international study. Leukemia. 2009;23:323\u201331.","journal-title":"Leukemia"},{"key":"662_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","volume":"151","author":"CY Lin","year":"2012","unstructured":"Lin CY, Loven J, Rahl PB, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012;151:56\u201367.","journal-title":"Cell"},{"key":"662_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cell.2012.08.033","volume":"151","author":"Z Nie","year":"2012","unstructured":"Nie Z, Hu G, Wei G, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012;151:68\u201379.","journal-title":"Cell"},{"key":"662_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1097-2765(00)80367-6","volume":"4","author":"DW Felsher","year":"1999","unstructured":"Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999;4:199\u2013207.","journal-title":"Mol Cell"},{"key":"662_CR17","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1073\/pnas.96.7.3940","volume":"96","author":"DW Felsher","year":"1999","unstructured":"Felsher DW, Bishop JM. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci USA. 1999;96:3940\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"662_CR18","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/ijc.20099","volume":"110","author":"D Marinkovic","year":"2004","unstructured":"Marinkovic D, Marinkovic T, Mahr B, et al. Reversible lymphomagenesis in conditionally c-MYC expressing mice. Int J Cancer. 2004;110:336\u201342.","journal-title":"Int J Cancer"},{"key":"662_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1126\/science.1073096","volume":"297","author":"IB Weinstein","year":"2002","unstructured":"Weinstein IB. Cancer. Addiction to oncogenes\u2014the Achilles heal of cancer. Science. 2002;297:63\u20134.","journal-title":"Science"},{"key":"662_CR20","doi-asserted-by":"publisher","first-page":"16266","DOI":"10.1073\/pnas.0608017103","volume":"103","author":"S Giuriato","year":"2006","unstructured":"Giuriato S, Ryeom S, Fan AC, et al. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci USA. 2006;103:16266\u201371.","journal-title":"Proc Natl Acad Sci USA"},{"key":"662_CR21","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.1073\/pnas.79.24.7824","volume":"79","author":"R Dalla-Favera","year":"1982","unstructured":"Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA. 1982;79:7824\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"662_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0092-8674(02)01284-9","volume":"112","author":"SK Nair","year":"2003","unstructured":"Nair SK, Burley SK. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell. 2003;112:193\u2013205.","journal-title":"Cell"},{"key":"662_CR23","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1039\/c002534h","volume":"6","author":"KC Jeong","year":"2010","unstructured":"Jeong KC, Ahn KO, Yang CH. Small-molecule inhibitors of c-Myc transcriptional factor suppress proliferation and induce apoptosis of promyelocytic leukemia cell via cell cycle arrest. Mol BioSyst. 2010;6:1503\u20139.","journal-title":"Mol BioSyst"},{"key":"662_CR24","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1177\/1947601910377494","volume":"1","author":"EV Prochownik","year":"2010","unstructured":"Prochownik EV, Vogt PK. Therapeutic targeting of Myc. Genes Cancer. 2010;1:650\u20139.","journal-title":"Genes Cancer"},{"key":"662_CR25","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1158\/0008-5472.CAN-04-3981","volume":"65","author":"T Hata","year":"2005","unstructured":"Hata T, Furukawa T, Sunamura M, et al. RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. 2005;65:2899\u2013905.","journal-title":"Cancer Res"},{"key":"662_CR26","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1182\/blood-2009-11-251074","volume":"116","author":"J den Hollander","year":"2010","unstructured":"den Hollander J, Rimpi S, Doherty JR, et al. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood. 2010;116:1498\u2013505.","journal-title":"Blood"},{"key":"662_CR27","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/nm.4107","volume":"22","author":"D Dauch","year":"2016","unstructured":"Dauch D, Rudalska R, Cossa G, et al. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Nat Med. 2016;22:744\u201353.","journal-title":"Nat Med"},{"key":"662_CR28","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1182\/blood-2009-12-259523","volume":"115","author":"G Gorgun","year":"2010","unstructured":"Gorgun G, Calabrese E, Hideshima T, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010;115:5202\u201313.","journal-title":"Blood"},{"key":"662_CR29","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2012.02.053","volume":"149","author":"JS Duncan","year":"2012","unstructured":"Duncan JS, Whittle MC, Nakamura K, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 2012;149:307\u201321.","journal-title":"Cell"},{"key":"662_CR30","first-page":"2161","volume":"7","author":"A Duthu","year":"1992","unstructured":"Duthu A, Debuire B, Romano J, et al. p53 mutations in Raji cells: characterization and localization relative to other Burkitt\u2019s lymphomas. Oncogene. 1992;7:2161\u20137.","journal-title":"Oncogene"},{"issue":"Pt 5","key":"662_CR31","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1099\/0022-1317-74-5-803","volume":"74","author":"KH Vousden","year":"1993","unstructured":"Vousden KH, Crook T, Farrell PJ. Biological activities of p53 mutants in Burkitt\u2019s lymphoma cells. J Gen Virol. 1993;74(Pt 5):803\u201310.","journal-title":"J Gen Virol"},{"key":"662_CR32","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1158\/2159-8290.CD-16-0653","volume":"7","author":"JS Zawistowski","year":"2017","unstructured":"Zawistowski JS, Bevill SM, Goulet DR, et al. Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex. Cancer Discov. 2017;7:302\u201321.","journal-title":"Cancer Discov"},{"key":"662_CR33","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa055351","volume":"354","author":"M Hummel","year":"2006","unstructured":"Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt\u2019s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419\u201330.","journal-title":"N Engl J Med"},{"key":"662_CR34","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/ng.2468","volume":"44","author":"C Love","year":"2012","unstructured":"Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44:1321\u20135.","journal-title":"Nat Genet"},{"key":"662_CR35","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"662_CR36","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3452\u20139.","journal-title":"J Clin Oncol"},{"key":"662_CR37","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.18632\/oncotarget.3245","volume":"6","author":"RJ Diaz","year":"2015","unstructured":"Diaz RJ, Golbourn B, Faria C, et al. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma. Oncotarget. 2015;6:3359\u201374.","journal-title":"Oncotarget"},{"key":"662_CR38","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-11-2413","volume":"18","author":"D Mahadevan","year":"2012","unstructured":"Mahadevan D, Stejskal A, Cooke LS, et al. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2012;18:2210\u20139.","journal-title":"Clin Cancer Res"},{"key":"662_CR39","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1158\/1535-7163.MCT-11-0623","volume":"11","author":"V Sehdev","year":"2012","unstructured":"Sehdev V, Peng D, Soutto M, et al. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther. 2012;11:763\u201374.","journal-title":"Mol Cancer Ther"},{"key":"662_CR40","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccell.2015.06.001","volume":"28","author":"C Topham","year":"2015","unstructured":"Topham C, Tighe A, Ly P, et al. MYC is a major determinant of mitotic cell fate. Cancer Cell. 2015;28:129\u201340.","journal-title":"Cancer Cell"},{"key":"662_CR41","doi-asserted-by":"publisher","first-page":"e108758","DOI":"10.1371\/journal.pone.0108758","volume":"9","author":"M Michaelis","year":"2014","unstructured":"Michaelis M, Selt F, Rothweiler F, et al. Aurora kinases as targets in drug-resistant neuroblastoma cells. PLoS ONE. 2014;9:e108758.","journal-title":"PLoS ONE"},{"key":"662_CR42","doi-asserted-by":"publisher","first-page":"9846","DOI":"10.1158\/0008-5472.CAN-10-3001","volume":"70","author":"M Payton","year":"2010","unstructured":"Payton M, Bush TL, Chung G, et al. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010;70:9846\u201354.","journal-title":"Cancer Res"},{"key":"662_CR43","doi-asserted-by":"publisher","first-page":"146282","DOI":"10.1155\/2015\/146282","volume":"2015","author":"MM Mc Gee","year":"2015","unstructured":"Mc Gee MM. Targeting the mitotic catastrophe signaling pathway in cancer. Mediators Inflamm. 2015;2015:146282.","journal-title":"Mediators Inflamm"},{"key":"662_CR44","first-page":"1627","volume":"9","author":"JP Li","year":"2015","unstructured":"Li JP, Yang YX, Liu QL, et al. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2\/M arrest, apoptosis, and autophagy via p38 MAPK and Akt\/mTOR signaling pathways in human breast cancer cells. Drug Des Devel Ther. 2015;9:1627\u201352.","journal-title":"Drug Des Devel Ther"},{"key":"662_CR45","doi-asserted-by":"publisher","first-page":"11653","DOI":"10.18632\/oncotarget.2605","volume":"5","author":"A McCarthy","year":"2014","unstructured":"McCarthy A, Marzec J, Clear A, et al. Dysregulation of autophagy in human follicular lymphoma is independent of overexpression of BCL-2. Oncotarget. 2014;5:11653\u201368.","journal-title":"Oncotarget"},{"key":"662_CR46","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ccr.2006.06.001","volume":"10","author":"K Degenhardt","year":"2006","unstructured":"Degenhardt K, Mathew R, Beaudoin B, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 2006;10:51\u201364.","journal-title":"Cancer Cell"},{"key":"662_CR47","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1186\/s12885-016-2906-9","volume":"16","author":"A Belounis","year":"2016","unstructured":"Belounis A, Nyalendo C, Le Gall R, et al. Autophagy is associated with chemoresistance in neuroblastoma. BMC Cancer. 2016;16:891.","journal-title":"BMC Cancer"},{"key":"662_CR48","doi-asserted-by":"publisher","first-page":"e838","DOI":"10.1038\/cddis.2013.350","volume":"4","author":"X Sui","year":"2013","unstructured":"Sui X, Chen R, Wang Z, et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 2013;4:e838.","journal-title":"Cell Death Dis"},{"key":"662_CR49","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1007\/s10637-018-0625-6","volume":"36","author":"M Carducci","year":"2018","unstructured":"Carducci M, Shaheen M, Markman B, et al. A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. Invest New Drugs. 2018;36:1060\u201371.","journal-title":"Invest New Drugs"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-019-00662-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-019-00662-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-019-00662-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T20:01:10Z","timestamp":1597694470000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-019-00662-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,19]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["662"],"URL":"https:\/\/doi.org\/10.1007\/s11523-019-00662-4","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,19]]},"assertion":[{"value":"19 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by the American Cancer Society Mentored Research Scholar Grant in Tumor Biology and Genomics (126601-MRSG-14-215-01-TBG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Steven Park reports receiving research funding from Seattle Genetics, Teva, Takeda, and BMS, membership of speakers bureau for Gilead and Seattle Genetics, and membership on Board of Directors or advisory committee for Rafael Pharmaceuticals, BMS, and Teva (advisory boards). Carolina Lin, Natalie Ren, Steven Angus, Dirk Dittmer, Michael Foote, Trevor Parton, Aadra Bhatt, Yuri Fedoriw, Daniel Roth, Marissa Cann, and Gary Johnson have no conflicts of interest to disclose.\u00a0Blossom Damania is a consultant for Arqule Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}